Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer

Author： Bordoni Rodolfo E  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.8, Iss.1, 2011-01, pp. : 15-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 37, Iss. 5, 2014-04 ,pp. : 262-265

Karger

Access to resources Recommend Favorite

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 7-13

Karger

Access to resources Recommend Favorite

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3761-3768

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular Pathology of Non-Small-Cell Lung Cancer

By  

Respiration, Vol. 72, Iss. 3, 2005-06 ,pp. : 313-330

Karger

Access to resources Recommend Favorite

Hycamtin in the Therapy of Non-Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 18-21

Karger

Access to resources Recommend Favorite